avatar

Christoph U. Correll, MD - Transforming the Treatment of Schizophrenia: Moving Beyond Anti-Dopaminergic Antipsychotics to Muscarinic Receptor Agonists

CME in Minutes: Education in Primary Care
CME in Minutes: Education in Primary Care
Episode • Nov 6, 2024 • 15m
Please visit answersincme.com/DKN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in psychiatry discusses antipsychotics in schizophrenia. Upon completion of this activity, participants should be better able to: Explain the rationale for targeting muscarinic receptors in the treatment of schizophrenia; Describe the clinical implications of evidence on muscarinic receptor agonists in the treatment of schizophrenia; and Outline strategies for optimally incorporating muscarinic receptor agonists into the treatment of patients with schizophrenia.

Switch to the Fountain App